Related Experiment Video
Updated: Jan 14, 2026
06:39
Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
Published on: October 3, 2018
10.1K
Myelodysplastic syndromes: Updates on Genomic Landscape, Molecular Subtypes, & Targeted Therapies
1Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
Current Hematologic Malignancy Reports
|October 27, 2025
Summary
Myelodysplastic syndromes (MDS) are complex, driven by numerous mutations. Advances in genomic testing reveal molecular subtypes, guiding new targeted therapies for lower-risk MDS, while high-risk options remain limited.
Area of Science:
- Hematology
- Genomics
- Oncology
Background:
- Myelodysplastic syndromes (MDS) are clonal hematopoietic stem cell disorders.
- Genetic complexity and molecular heterogeneity characterize MDS pathogenesis.
Purpose of the Study:
- Review diagnostic methods in MDS.
- Explore the multi-omics landscape and molecular subtypes of MDS.
- Discuss emerging targeted therapies for MDS.
Main Methods:
- Review of current literature on MDS.
- Analysis of genomic and molecular data.
- Evaluation of diagnostic and therapeutic advancements.
Main Results:
- MDS exhibits diverse chromosomal abnormalities and over 40 common somatic mutations.
- Genetic subgroups (del(5q), SF3B1, TP53-mutated) are now part of WHO/ICC classification.
- New targeted therapies like luspatercept and imetelstat benefit lower-risk MDS.
Conclusions:
- Genomic insights are transforming MDS understanding and classification.
- Targeted therapies offer new hope for lower-risk MDS patients.
- Further research is crucial for effective high-risk MDS treatments.
